PRADER-WILLI SYNDROME
Clinical trials for PRADER-WILLI SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PRADER-WILLI SYNDROME trials appear
Sign up with your email to follow new studies for PRADER-WILLI SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug safety check for rare genetic condition
Disease control ENROLLING_BY_INVITATIONThis study looks at the safety of the drug pitolisant in 150 people with Prader-Willi syndrome who have already completed a related study. Participants will take pitolisant and be monitored for side effects. The goal is to see how safe the drug is for long-term use in this condit…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Disease control
Last updated May 17, 2026 03:15 UTC
-
New drug under watch for Prader-Willi syndrome
Disease control ENROLLING_BY_INVITATIONThis study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers want to see how safe the drug is and how patients do over time. The goal is to learn more, not to test if the drug works as a cure.
Matched conditions: PRADER-WILLI SYNDROME
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising drug targets severe hunger and obesity in rare genetic disorder
Disease control OngoingThis study tests a daily injection called setmelanotide in people aged 6 to 65 with Prader-Willi syndrome, a genetic condition causing severe obesity and constant hunger. The goal is to see if the drug is safe and helps reduce body weight and hunger over 52 weeks. Up to 18 partic…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for rare hunger disorder: 12-Month drug trial launches
Disease control TerminatedThis study tests whether a daily medication called ARD-101 can safely reduce the intense, constant hunger (hyperphagia) that people with Prader-Willi syndrome experience. About 90 participants who completed a prior study will take the drug for up to 12 months. Researchers will tr…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for rare hunger disorder: ARD-101 trial launches
Symptom relief TerminatedThis study tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either the drug or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a questionnaire. …
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
Could a simple ear device tame outbursts in Prader-Willi syndrome?
Symptom relief OngoingThis study tests a small device that gently stimulates a nerve in the ear (vagus nerve) to see if it can safely reduce temper outbursts in people with Prader-Willi syndrome. About 102 participants aged 10 to 40 will use the device daily. The goal is to improve emotional control a…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Foundation for Prader-Willi Research • Aim: Symptom relief
Last updated May 14, 2026 12:05 UTC
-
New hope for daytime sleepiness in Prader-Willi syndrome?
Symptom relief OngoingThis study tests a drug called pitolisant to see if it can safely reduce severe daytime sleepiness in people with Prader-Willi syndrome, a genetic condition. About 65 participants aged 6 to 65 will receive either pitolisant or a placebo for 11 weeks, followed by an open-label pha…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE2 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated May 12, 2026 13:43 UTC